AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX).
週四，Exscientia plc（納斯達克：EXAI）同意與Recursion Pharmaceuticals Inc.（納斯達克：RXRX）合併。
Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, with fractional shares paid in cash.
Exscientia股東將以0.7729個Recursion股票換取每個Exscientia股票，碎股以現金支付。
Based on the fixed exchange ratio, Recursion shareholders will own approximately 74% of the combined entity, and Exscientia shareholders will own approximately 26%.
基於固定的交換比率，Recursion股東將擁有合併實體的大約74％，而Exscientia股東將擁有大約26％。
Also Read: Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism.
同時閱讀：英偉達動力的超級計算機完成引發投資者樂觀情緒，Recursion Pharmaceuticals股票飆升10％。
"We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high-quality medicines and lower prices for consumers," said Chris Gibson, Co-Founder and CEO of Recursion and the planned CEO of the combined entity.
「我們相信擬議中的組合與我們的任務深度補充和對齊，即將產業化藥物研發，爲消費者提供高質量醫藥並降低價格，」Recursion的聯合創始人兼首席執行官Chris Gibson說，他是合併實體的計劃CEO。
The combined company, which will be named Recursion, will continue to be headquartered in Salt Lake City, Utah, and trade on the NASDAQ while maintaining a significant presence in the U.K.
合併後的公司將命名爲Recursion，總部位於猶他州鹽湖城，在納斯達克上交易，同時保持在英國的重要存在。
Chris Gibson, Co-Founder & CEO of Recursion, will serve as CEO of the combined company and David Hallett, Interim Chief Executive Officer & Chief Scientific Officer of Exscientia, plans to join the combined company as Chief Scientific Officer.
Recursion的聯合創始人兼首席執行官Chris Gibson將擔任合併公司的CEO，而Exscientia的代理首席執行官兼首席科學家David Hallett計劃加入合併公司擔任首席科學家。
Related: AI Drug Hunter Firm Exscientia Fires Its CEO Over 'Inappropriate' Relationships with Two Employees.
相關：AI藥物獵人公司Exscientia因與兩名員工有不當關係而解僱其首席執行官。
Exscientia will bring its precision chemistry design and small-molecules automated synthesis technology to Recursion, contributing to scaled biology exploration and translational capabilities.
Exscientia將其精密化學設計和小分子自動合成技術帶到Recursion，爲擴大的生物學探索和轉化能力做出貢獻。
Once integrated, the companies believe the extended and evolved Recursion Operating System will enable the discovery and translation of higher-quality medicines more efficiently and at a higher scale with a full-stack technology-enabled small molecule discovery platform.
一旦整合，雙方公司相信擴展和改進的Recursion操作系統將利用全棧技術啓用的小分子發現平台更加高效地發現和轉化高質量醫藥。
In addition, the combined company expects to read out approximately ten clinical trials in the next 18 months, where most of these programs, if successful, could have annual peak sales opportunities in excess of $1 billion.
此外，合併後的公司預計在接下來的18個月內獲得約10項臨床試驗結果，如果成功，其中大多數項目的年銷售額機會超過10億美元。
The combined entity will have $850 million in cash and about $200 million in expected milestones over the next 24 months, plus a potential $20 billion in royalties on the line later if any drugs from the pipeline are approved.
合併實體將擁有8500萬美元的現金和未來24個月內的約2000萬美元的預期里程碑，以及在管道中有任何藥物獲批後可能達到200億美元的版稅。
The combined company is estimated to achieve approximately $100 million in annual synergies with a runway extending into 2027.
預計合併公司將實現約1億美元的年度協同效應，並可延續至2027年。
Price Action: On Thursday, EXAI stock closed 17.1% higher to $5.27.
價格行動：星期四，EXAI股票收盤上漲17.1％至5.27美元。
- Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects.
- 由於效果不佳和副作用，默沙東停止開展Keytruda聯合用於肺癌的研究。
Photo by Capri23auto from Pixabay
Photo by Capri23auto from Pixabay
